Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels
Launched by NUVASIVE · Jan 11, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Subject was enrolled in the Simplify Disc IDE (NCT03123549) and/or PAS (NCT04980378) at a participating study site
- • 2. Patient understands the conditions of enrollment and is willing sign an informed consent form to participate in the study
- Exclusion Criteria:
- • 1. Subject had an SSI at the index level during the IDE study (NCT03123549) or the PAS (NCT04980378)
- • 2. Subject was withdrawn or withdrew consent to participate in the IDE study (NCT03123549) or PAS (NCT04980378)
About Nuvasive
NuVasive is a leading medical device company specializing in innovative solutions for spine surgery. Committed to advancing surgical techniques and improving patient outcomes, NuVasive develops cutting-edge technologies and products that enhance the efficiency and effectiveness of spinal procedures. The company’s focus on research and development, combined with a robust clinical trial portfolio, underscores its dedication to evidence-based practices and continuous improvement in the field of spinal healthcare. Through collaboration with healthcare professionals and a commitment to education, NuVasive aims to transform the landscape of spine surgery and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Plano, Texas, United States
Charlotte, North Carolina, United States
Patients applied
Trial Officials
Kyle Malone
Study Director
NuVasive
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials